Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled dose-finding study of LS001 in early to mid-stage Parkinson's disease
CTR20212522Phase 2Active
- Sponsor
- Institute of Pharmacology and Toxicology, Academy of Military Medical Sciences
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing LS001 with Placebo (2 arms). Primary endpoints: Safety assessments and Adverse events. Started Jan 2022; status: active.
02
Drugs
levo-demethylphencynonate hydrochloride
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on CTR20212522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212522.